Business Context and Reporting Period
This Form 8-K was filed by Atricure, Inc. on December 16, 2011. The report addresses a specific corporate event rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory approval event.
Material Changes
On December 16, 2011, the U.S. Food and Drug Administration (FDA) approved Atricure's Synergy Ablation System for the treatment of atrial fibrillation. This approval represents a significant milestone for the company's product portfolio.
Guidance, Outlook, and Risks
The filing incorporates a press release (Exhibit 99.1) detailing the FDA approval. No specific financial guidance, management outlook, risk factors, or contingencies are disclosed within the text of this Form 8-K.
Investor Verification Points
- Verify the specific indications and limitations of the FDA approval for the Synergy Ablation System.
- Review the full text of the press release filed as Exhibit 99.1 for commercialization timelines.
- Assess the potential impact of this approval on the company's future revenue streams and competitive position.